The Los Angeles Post
U.S. World Business Lifestyle
Today: March 16, 2025
Today: March 16, 2025
Bhanvi Satija

Bhanvi Satija

Staff Writer

Latest From Bhanvi Satija

Americas|Health|US

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads

Measles cases in Texas and New Mexico rose to 294 on Friday, surpassing all U.S. cases recorded in 2024, as an outbreak that began in late January in West Texas spreads. 

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads
Health|US

Measles cases in Texas, New Mexico rise by 28 in five days as outbreak spreads

Texas and New Mexico on Tuesday reported an increase of 28 cases of measles in the last five days, bringing the total known infections to 256 in the two states since an

Measles cases in Texas, New Mexico rise by 28 in five days as outbreak spreads
Health|US|World

Texas, New Mexico report increase in measles cases

Texas and New Mexico on Friday reported an additional 59 cases of measles for a total of 228 known infections in those states, where an outbreak that began in West Texas in

Texas, New Mexico report increase in measles cases
Health|Political|US

Unvaccinated New Mexico adult tests positive for measles after death

A New Mexico resident who has died, tested positive for measles, the state health department said on Thursday, marking the second measles-related

Unvaccinated New Mexico adult tests positive for measles after death
Asia|Business|Health|Science

India on the verge of becoming clinical trials hub, Parexel executive says

India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions such as the Russia

India on the verge of becoming clinical trials hub, Parexel executive says
Business|Economy|Health|Political|Technology|US

Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats

Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of

Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Health|Political|Science|US

US health agencies postpone rare diseases event in an unusual move

A two-day meeting aimed at raising awareness among policymakers and public about rare diseases scheduled for the end of the month has been postponed,

US health agencies postpone rare diseases event in an unusual move
Business|Economy|Health|US

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

The U.S.

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
Business|Economy|Health|Science

Next generation weight loss drugs aim to save muscle

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors

Next generation weight loss drugs aim to save muscle
Business|Economy|Finance|Health|Stock Markets|US

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about

Lilly reassures investors that weight-loss drug demand is strong, shares rise
Business|Economy|Finance|Health|Stock Markets

Pfizer shows profit growth from cost cuts and steadier COVID sales

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors

Pfizer shows profit growth from cost cuts and steadier COVID sales
Business|Finance|Health|US

J&J beats quarterly sales and profit estimates on cancer drug sales

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter revenues and profit above Wall

J&J beats quarterly sales and profit estimates on cancer drug sales
Business|Finance|Health

J&J profit edges past Street view after deals delay Stelara competition

Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug

J&J profit edges past Street view after deals delay Stelara competition
Business|Health|News|US

Explainer-Why are Kaiser Permanente healthcare workers on strike?

About 75,000 medical workers from Kaiser Permanente facilities went on a planned three-day strike on Wednesday, putting pressure on one of the leading not-

Explainer-Why are Kaiser Permanente healthcare workers on strike?
Business|Finance|Health|US

UnitedHealth profit beats on lower-than-feared medical costs

UnitedHealth reported a third-quarter profit on Friday ahead of analysts' estimates, helped by a lower-than-feared rise in medical costs at the company's

UnitedHealth profit beats on lower-than-feared medical costs
Business|Health

J&J to restructure orthopedic business after medical device sales miss

Johnson & Johnson on Tuesday said it has embarked on a two-year restructuring program for its orthopedics business after third-quarter medical devices

J&J to restructure orthopedic business after medical device sales miss
Business|Finance|Health

Pfizer looks beyond COVID after quarterly loss on Paxlovid charge

Pfizer on Tuesday urged investors to focus on growth in non-COVID products such as the new RSV vaccine Abrysvo as slumping demand for COVID-19 vaccines

Pfizer looks beyond COVID after quarterly loss on Paxlovid charge
Business|Economy|Health

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
Business|Finance|Stock Markets|US

Retail investors crowd into Eli Lilly after weight-loss drug approval

Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major

Retail investors crowd into Eli Lilly after weight-loss drug approval
Business|Finance|Health|US

Wegovy craze was all the rage on Q3 earnings calls

Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across

Wegovy craze was all the rage on Q3 earnings calls
Business|Health

AbbVie's $8.7 billion bet on Cerevel is risky but smart, analysts say

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a

AbbVie's $8.7 billion bet on Cerevel is risky but smart, analysts say
Business|Finance|Health

Lilly rides wave of weight-loss drug demand, working to expand capacity

Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for Zepbound, its recently approved weight-loss drug, and said

Lilly rides wave of weight-loss drug demand, working to expand capacity
Economy|Health|US

US hospitals see post pandemic catch-up behind insurer healthcare costs

Americans are catching up on healthcare missed during the COVID-19 pandemic, a trend driven by heart procedures and outpatient orthopedic surgeries that

US hospitals see post pandemic catch-up behind insurer healthcare costs
Health|News|Science|World

Global fertility rates to decline, shifting population burden to low-income countries

Fertility rates in nearly all countries will be too low to sustain population levels by the end of the century, and most of the world's live births will be occurring in

Global fertility rates to decline, shifting population burden to low-income countries
Business|Finance|Health

Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion

Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by

Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion

Follow